Question 1

What is Relmada Therapeutics's P/B ratio?

Accepted Answer

Relmada Therapeutics (RLMD) P/B ratio is 2.6× as of June 12, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for Relmada Therapeutics?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For Relmada Therapeutics specifically, the relevant sector benchmark is the current sector median of 3.4×.

Question 5

Is Relmada Therapeutics's P/B ratio high or low?

Accepted Answer

Relmada Therapeutics's P/B ratio of 2.6× is above its own 5-year average of 1.2× and below the sector median of 3.4×. That places the current reading at the 85th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Relmada Therapeutics's historical P/B ratio range?

Accepted Answer

In the available daily series, Relmada Therapeutics (RLMD) P/B ratio has ranged from a low of 0.1× in 2022 to a high of 25.1× in 2026. The 5-year average is 1.2× and the 5-year median is 0.5×.

Question 7

What was Relmada Therapeutics's P/B ratio in 2025?

Accepted Answer

Relmada Therapeutics (RLMD) P/B ratio at the end of 2025 was 3.8×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does Relmada Therapeutics's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$329.67M	$86.51M	3.8×	+3.4×	Dec 31, 2025
2024	$15.69M	$35.52M	0.4×	+0.1×	Dec 31, 2024
2023	$31.00M	$85.36M	0.4×	+0.2×	Dec 31, 2023
2022	$26.26M	$140.44M	0.2×	-0.2×	Dec 31, 2022
2021	$86.06M	$208.26M	0.4×	-0.6×	Dec 31, 2021
2020	$104.25M	$105.58M	1.0×	+0.2×	Dec 31, 2020
2019	$88.68M	$115.68M	0.8×	-3.3×	Dec 31, 2019
2018	$5.88M	$1.43M	4.1×	+1.5×	Dec 31, 2018
2017	$1.88M	$721.16K	2.6×	+2.0×	Dec 31, 2017
2016	$2.62M	$4.67M	0.6×	+0.1×	Dec 31, 2016
2015	$5.71M	$11.76M	0.5×	-6.4×	Dec 31, 2015
2014	$31.47M	$4.59M	6.9×	—	Dec 31, 2014
2013	$17.10M	−$28.03K	—	—	Nov 30, 2013
2012	$17.10M	—	—	—	Nov 30, 2012


Spruce Biosciences (SPRB)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Danaher (DHR)	2.4×
UnitedHealth Group (UNH)	2.4×
Solventum (SOLV)	2.3×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Molina Healthcare (MOH)	1.7×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Elevance Health (ELV)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Revvity (RVTY)	1.4×
Zimmer Biomet Holdings (ZBH)	1.2×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Ovid Therapeutics (OVID)	0.8×
Centene (CNC)	0.8×
Teladoc Health (TDOC)	0.7×

P/B Ratio for Relmada Therapeutics (RLMD)

P/B Ratio daily chart for Relmada Therapeutics (RLMD)

Historical P/B Ratio for Relmada Therapeutics (RLMD) from 2012 to 2025

About P/B Ratio at Relmada Therapeutics (RLMD)

Relmada Therapeutics P/B Ratio by Year

Relmada Therapeutics P/B Ratio 2025: 3.8×

Relmada Therapeutics P/B Ratio 2024: 0.4×

Relmada Therapeutics P/B Ratio 2023: 0.4×

Relmada Therapeutics P/B Ratio 2022: 0.2×

Relmada Therapeutics P/B Ratio 2021: 0.4×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

Relmada Therapeutics (RLMD) Key Financials

P/B Ratio daily chart for Relmada Therapeutics (RLMD)

Historical P/B Ratio for Relmada Therapeutics (RLMD) from 2012 to 2025

About P/B Ratio at Relmada Therapeutics (RLMD)

Relmada Therapeutics P/B Ratio by Year

Relmada Therapeutics P/B Ratio 2025: 3.8×

Relmada Therapeutics P/B Ratio 2024: 0.4×

Relmada Therapeutics P/B Ratio 2023: 0.4×

Relmada Therapeutics P/B Ratio 2022: 0.2×

Relmada Therapeutics P/B Ratio 2021: 0.4×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

+What is Relmada Therapeutics's P/B ratio?

+How is the P/B ratio calculated?

+What is the P/B ratio?

+What is a good P/B ratio for Relmada Therapeutics?

+Is Relmada Therapeutics's P/B ratio high or low?

+What is Relmada Therapeutics's historical P/B ratio range?

+What was Relmada Therapeutics's P/B ratio in 2025?

+Why does Relmada Therapeutics's P/B ratio change over time?

Relmada Therapeutics (RLMD) Key Financials